Drug intelligence / Profile preview

indomethacin + naproxen

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

This drug is a combination of two nonsteroidal anti-inflammatory drugs (NSAIDs), indomethacin and naproxen. Both agents work by inhibiting cyclo-oxygenase enzymes, which reduces prostaglandin synthesis, leading to decreased inflammation, pain, and fever. Indomethacin is used for conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gouty arthritis, bursitis, tendinitis, and closure of patent ductus arteriosus in premature infants. Naproxen is indicated for similar inflammatory conditions including rheumatoid arthritis and osteoarthritis as well as acute gout and dysmenorrhea. The combination has been studied in coamorphous forms to improve physical stability and dissolution rates compared to the individual drugs alone. However, concomitant use of these two NSAIDs is generally not recommended due to increased risk of serious side effects such as gastrointestinal ulcers or bleeding[1][4][5][6][9].

Other names
indomethacin and naproxen
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on indomethacin + naproxen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on indomethacin + naproxen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call